Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 686

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 686
---
,503 noted in the calculation above based on actual and assumed cash payments to-date that are creditable against the cash component of the Merger Consideration, as well as the current estimated net working capital deficit (assumed to be the maximum allowed amount of $6,000,000), the Initial Share Consideration expected is $15,755,497 (consisting of the maximum value of $16,500,000 less the Deficit Cash Consideration expected of $744,503) which translates to 2,738,751 shares of TuHURA Common Stock being issued ($15,755,497 divided by the TuHURA Share Value of approximately $5.7528). Subject to further adjustment based on subsequent changes to the delayed net working capital or other amounts which could update the calculation of Merger Consideration pursuant to the amended Merger Agreement, the Delayed Share Consideration is still expected to be the maximum value of $6,500,000

<div align='center'>446</div>

### NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
**which translates to an additional 1,129,884 shares of TuHURA Common Stock being issued ($6,500,000 divided by the TuHURA Share Value of approximately $5.7528); for an aggregate share consideration calculated of 3,868,635 shares of TuHURA Common Stock to be issued (as calculated through the issuance of 2,738,751 shares as the Initial Share Consideration plus the 1,129,884 shares as the Delayed Share Consideration) estimated on a pro forma basis using the relevant details included in this unaudited pro forma condensed combined financial information.

As additional estimated contingent consideration, Kineta stockholders will be entitled to receive their pro rata share of certain payments in cash that Kineta may receive after the Closing of the Mergers from the potential pre-closing sale by Kineta of certain non-KVA12123 products and technologies (the “Disposed Asset Payment Right”).

Based on the current stage of clinical trials and inherent uncertainties surrounding the further development, regulatory approval, or viability of being able to enter into an agreement to dispose of any non-VISTA Assets and any other agreement entered into by the Company prior to the Closing in connection with a Permitted Asset Disposition, as defined in the Merger Agreement, including the likelihood of certain clinical and/or regulatory milestones being achieved with regard to the agreements entered into with third parties surrounding the disposal